Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival

Oncotarget

Volumn 4, Issue 8, 2013, Pages 1230-1240

  Reghunathan, Renji ^a   Bi, Chonglei ^b   Liu, Shaw Cheng ^c   Loong, Koh Tze ^d   Chung, Tae Hoon ^b   Huang, Gaofeng ^b   Chng, Wee Joo ^a,b,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c Singapore Science Park II   (Singapore)

^d NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Differentiation; Myeloma; Plasma cells; Proliferation; Stemness

Indexed keywords

3 DEAZANEPLANOCIN A; ALDEHYDE DEHYDROGENASE; POLYCOMB GROUP PROTEIN; SYNDECAN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURVIVAL; CELL DIFFERENTIATION; CLINICAL ARTICLE; CLONOGENESIS; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LEUKEMIC STEM CELLS; MOUSE; MULTIPLE MYELOMA; NONHUMAN; STEM CELL;

ALDEHYDE DEHYDROGENASE; ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CLONE CELLS; CULTURE MEDIA; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; MULTIPLE MYELOMA; NEOPLASTIC STEM CELLS; SURVIVAL ANALYSIS; SYNDECAN-1; TUMOR CELLS, CULTURED;

EID: 84884327949     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1145     Document Type: Article

References (51)

1. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007; 7: 585-598.
2. Chng WJ, Van Wier SA, Ahmann GJ, Winkler JM, JalalSM, Bergsagel PL, Chesi M, Trendle MC, Oken MM, Blood E, Henderson K, Santana-Dávila R, Kyle RA, Gertz MA, Lacy MQ, Dispenzieri A et al. A validated FISH Trisomy Index Demonstrates the Hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood. 2005; 106: 2156- 216.
3. Chng WJ, Santana-Dávila R, Van Wier SA, Ahmann GJ, Jalal SM, Bergsagel PL. Prognostic factors for hyper diploid myeloma: IgH translocations but not chromosome 13 deletion negatively impact survival in hyperdiploid myeloma. Leukemia. 2006; 20: 807-813.
4. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001; 1:105-111.
5. Huff CA, Matsui W. Multiple myeloma cancer stem cells. J Clin Oncol. 2008; 26: 2895-2900.
6. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, Smith BD, Civin CI, Jones RJ. Characterization of clonogenic multiple myeloma cells. Blood. 2004; 103: 2332-2336.
7. Epstein J. Myeloma stem cell phenotype: implications for treatment. Hematol Oncol Clin North Am. 1997; 11:43- 49.
8. Davies FE, Rawstron AC, Owen RG, Morgan GJ. Controversies surrounding the clonogenic origin of multiple myeloma. Br J Haematol.2000; 110: 240-241
9. Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, McNiece I, Lin L, Ambinder RF, Peacock C, Watkins DN, Huff CA, Jones RJ. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008; 68: 190-197.
10. Brennan SK, Wang Q, Tressler R, Harley C, Go N, Bassett E, Huff CA, Jones RJ, Matsui W. Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS One. 2010; 5(9). pii: e12487.
11. Chilosi M, Adami F, Lestan M, Montagna L, Cimarosto L, Semenzato G, Pizzolo G, Menestrina F. CD138/syndecan- 1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Mod Pathol. 1999; 12:1101-1106.
12. Wijdenes J, Vooijs WC, Clément C, Post J, Morard F, Vita N, Laurent P, Sun RX, Klein B, Dore JM. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol. 1996; 94: 318-323.
13. Calame KL. Plasma cells: finding new light at the end of B cell development. Nat Immunol. 2001; 2: 1103-1108.
14. Tarte K, De Vos J, Thykjaer T, Zhan F, Fiol G, Costes V, Rème T, Legouffe E, Rossi JF, Shaughnessy J Jr, ørntoft TF, Klein B. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood. 2002; 100:1113-1122.
15. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2:48-58.
16. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996; 183:1797-1806.
17. Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H, Liu Z, Su Y, Stass SA, Katz RL. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res. 2009; 7: 330-338
18. Pearce DJ, Taussig D, Simpson C, Bonnet D, Allen K, Rohatiner AZ, Bonnet D. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells. 2005; 6:752- 60.
19. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007; 15: 555-567.
20. Balicki D. Moving forward in human mammary stem cell biology and breast cancer prognostication using ALDH1. Cell Stem Cell. 2007; 15:485-7.
21. Sparmann A, Lohuizen MV. Polycomb silencers control cell fate, development and cancer, Nat Rev Cancer. 2006; 6: 846-856.
22. Fan T, Jiang S, Chng N, Alikhan A, Ni C, Lee CCR, Hornyak TJ. EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Mol Cancer Res. 2011; 9: 418- 29.
23. Tanaka S, Miyagi S, Sashida G, Chiba T, Yuan J, Mochizuki-Kashio M, Suzuki Y, Sugano S, Nakaseko C, Yokote K, Koseki H, Iwama A. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood. 2012; 120:1107-1117.
24. Larsson CA, Cote G, Quintas-Cardama A. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome. Mol Cancer Res. 2013 May 3. doi: 10.1158/1541-7786.MCR-12-0695.
25. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, Waghorn K, Zoi K, Ross FM, Reiter A, Hochhaus A, Drexler HG, Duncombe A, Cervantes F, Oscier D, Boultwood J et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010; 42:722-726.
26. Velichutina I, Shaknovich R, Geng H, Johnson NA, Gascoyne RD, Melnick AM, Elemento O. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood. 2010; 116(24):5247-5255.
27. Yan J, Ng SB, Tay JL, Lin B, Koh TL, Tan J, Selvarajan V, Liu SC, Bi C, Wang S, Choo SN, Shimizu N, Huang G, Yu Q, Chng WJ. EZH2 overexpression in natural killer /T-cell lymphoma confers growth advantage independently of histone methyltransferase activity. Blood.2013;121(22):4512-4520.
28. Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R , Zeng J, Li M, Fan H, Lin Y, Gu J, Ardayfio O, Zhang JH, Yan X, Fang J, Mi Y, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A. 2012; 26; 109:21360-21365.
29. Kotake Y, Cao R, Viatour P, Sage J, Zhang Y, Xiong Y . pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene. Genes Dev. 2007; 21:49-54.
30. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL Karuturi RK, Tan PB, Liu ET, Yu Q. Pharmacologic disruption of Polycomb repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes & Devel. 2007; 21:1050-1067.
31. Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, Kelly TK, Marquez VE, Jones PA. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther. 2009; 8(6):1579-1588.
32. Zhou J, Bi C, Cheong LL, Mahara S, Liu SC, Tay KG, Koh TL, Yu Q, Chng WJ. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood. 2011; 118:2830-2839.
33. Fuhler GM, Baanstra M, Chesikc D, Somasundaram R, Seckinger A, Hose D, Peppelenbosch MP, Bos NA. Bone marrow stromal cell interaction reduces Syndecan-1 expression and induces kinomic changes in myeloma cells. Exp Cell Res. 2010; 316:1816-1828.
34. Chaidos A, Barnes CP, Cowan G, May PC, Melo V, Hatjiharissi E, Papaioannou M, Harrington H, Doolittle H, Terpos E, Dimopoulos M, Abdalla S, Yarranton H, Naresh K, Foroni L, Reid A, et al. Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood. 2013; 21:318-28
35. Rumfelt LL, Zhou Y, Rowley BM, Shinton SA, Hardy RR.Lineage specification and plasticity in CD19- early B cell precursors. The J Exp Med. 2006; 203: 675-687.
36. Bantignies F, Cavalli G. Polycomb group proteins: repression in 3D. Trends Genet. 2011; 27(11):454-64.
37. Kalushkova A, Frykna M, Lemaire M, Fristedt C, Agarwal P, Eriksson M, Deleu S, Atadja P, Osterborg A, Nilsson K, Vanderkerken K, Oberg F, Jernberg-Wiklund H.. Polycomb target genes are silenced in multiple myeloma. PLoS ONE. 2010; 5(7) e11483.
38. Lund AH, van Lohuizen M. Polycomb complexes and silencing mechanisms. Curr Opin Cell Biol. 2004; 16:239- 246.
39. Kerppola TK. Polycomb group complexes - many combinations, many functions. Trends Cell Biol. 2009; 19:692-704.
40. Chen D, Zhao M, Mundy GR. Bone morphogenic proteins. Growth Factors.2004; 22:233-241.
41. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K.Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 2006; 20:1123-1136.
42. Xie Z, Bi C, Cheong LL, Liu SC, Huang G, Zhou J, Yu Q, Chen CS, Chng WJ. Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells. PLoS ONE. 2011; 6(6) e 21583.
43. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A 3rd, Diaz E, LaFrance LV, Mellinger M, Duquenne C, Tian X, Kruger RG, McHugh CF, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012; 492 (7427):108-112.
44. Zhao X, Lwin T, Zhang X, Huang A, Wang J, Marquez VE, Chen-Kiang S, Dalton WS, Sotomayor E, Tao J. Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. Leukemia. 2013 Mar 29. doi: 10.1038/leu.2013.94.
45. Wagner T, Jung M., New lysine methyltransferase drug targets in cancer. Nat Biotechnol. 2012; 30:622-623.
46. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol. 2010 Oct 13; 28:1069-1078
47. Boucher K, Parquet N, Widen R, Shain K, Baz R, Alsina M, Koomen J, Anasetti C, Dalton W, Perez LE.. Stemness of B cell progenitors in multiple myeloma bone marrow. Clin Cancer Res. 2012; 18:6155-6168.
48. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. PNAS. 2005; 102: 15545-15550.
49. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstråle M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003; 34: 267-273.
50. Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, Metzeler KH, Poeppl A, Ling V, Beyene J, Canty AJ, Danska JS, Bohlander SK, Buske C, Minden MD, Golub TR, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med. 2011. 17:1086-1093.
51. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using Real-Time Quantitative PCR and the 2-[Delta][Delta]CT method. Methods, 2001; 25(4):402 - 408.